Despite the number of people surviving after a stroke increasing in recent decades, there has been little change in rates of rehabilitation and recovery. Here we speak to global biopharmaceutical firm, Ipsen, about its efforts to address this. Thirty years ago, scientists working in a UK government defence facility discovered a neurotoxin —originating from the bacteria botulinum— which they realised could have medicinal uses.  From this a drug was developed which in the years since would be used in various ways for the treatment of movement disorders.  Today, botulinum toxin injections also known as Dysport®(abobotulinumtoxinA), are prescribed to help manage spasticity in stroke patients.  However, despite having access to this drug for the last three decades, there has been little movement in the rates of rehabilitation among stroke survivors.  Stroke remains the second leading cause of death and the third leading cause of combined death and disability across the world. This is a key area of focus for global biopharmaceutical firm, Ipsen, the manufacturer of Dysport®.  Vice president of Global Medical Affairs, Dr Hamzah Baig, leads a team of scientists and physicians who conduct clinical trials in partnership with key research institutions across the world with the aim of improving patient care. In this exclusive interview with Dr Baig, he shares his insights on why research into stroke rehabilitation has been neglected, the challenges facing physicians in this sector and what the future of stroke care should look like.